MCLEAN HOSPITAL
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $4.9M
- Transactions
- 190
- Companies
- 20
- Average per transaction
- $25,718
Who reported the payments
| Biogen | $1,721,318 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $827,007 |
| Takeda Pharmaceuticals U.S.A., Inc. | $807,864 |
| Alkermes, Inc. | $305,567 |
| Eli Lilly | $272,602 |
| Eisai Inc. | $242,916 |
| FHC, Inc. | $188,575 |
| Boehringer Ingelheim | $157,008 |
| Otsuka America Pharmaceutical, Inc. | $119,460 |
| Shire North American Group Inc | $91,000 |
| Neurocrine Biosciences, Inc. | $85,369 |
| Sunovion Pharmaceuticals Inc. | $40,299 |
| E.r. Squibb & Sons, L.L.C. | $14,866 |
| Sage Therapeutics, LLC | $5,000 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | $3,839 |
| EMD Millipore Corporation | $1,907 |
| Regeneron | $826 |
| Boehringer Ingelheim International GmbH | $630 |
| Fisher Scientific Company L.L.C. | $276 |
| AstraZeneca | $25 |